Faculty of Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Pediatrics, Division of Neonatology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
BMJ Open. 2022 Aug 25;12(8):e055292. doi: 10.1136/bmjopen-2021-055292.
Beta-blockers are often used during pregnancy to treat diseases such as pre-existing hypertension, arrhythmias or pregnancy-related hypertension. Since beta-blockers are able to cross the placenta and can pass into breast milk, they could potentially harm the neonate. Known potential neonatal side effects of maternal beta-blocker use are hypoglycaemia and bradycardia. This systematic review and meta-analysis aims to investigate the risk for neonatal hypoglycaemia and bradycardia after exposure to beta-blockers in utero or through lactation.
We will conduct a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A systematic electronic search will be conducted using EMBASE, Medline, Cochrane Central Register of Trials and Web of Science from initiation to April 2021. Our primary outcome will be the risk for hypoglycaemia or bradycardia in neonates exposed to beta-blockers in utero or through lactation in comparison with unexposed neonates. All articles will be screened by title and abstract twice by different independent review authors. Next, standardised methodological quality assessment will be conducted for each included article and finally a meta-analysis will be performed.
Ethical approval is not required. The results of this study will help to assess the need for postnatal glucose and heart rate monitoring of the neonate after maternal beta-blocker exposure. Our findings will be communicated to the target audience through peer-reviewed publication.
CRD42021264269.
β受体阻滞剂常用于治疗妊娠前已存在的高血压、心律失常或妊娠相关性高血压等疾病。由于β受体阻滞剂能够穿过胎盘并进入乳汁，因此可能对新生儿造成潜在危害。已知母亲使用β受体阻滞剂的潜在新生儿副作用包括低血糖和心动过缓。本系统评价和荟萃分析旨在调查胎儿期或通过哺乳期暴露于β受体阻滞剂后新生儿低血糖和心动过缓的风险。
我们将根据系统评价和荟萃分析的首选报告项目指南进行系统评价。将从开始到 2021 年 4 月，通过 EMBASE、Medline、Cochrane 临床试验中心注册库和 Web of Science 进行系统电子搜索。我们的主要结局将是与未暴露于β受体阻滞剂的新生儿相比，胎儿期或通过哺乳期暴露于β受体阻滞剂的新生儿发生低血糖或心动过缓的风险。两名不同的独立审查作者将对标题和摘要进行两次筛选。接下来，将对每个纳入的文章进行标准化方法学质量评估，最后进行荟萃分析。
不需要伦理批准。本研究的结果将有助于评估母亲使用β受体阻滞剂后新生儿是否需要进行产后血糖和心率监测。我们的研究结果将通过同行评审出版物传达给目标受众。
PROSPERO 注册号：CRD42021264269。
